We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amphion Innovations Plc | LSE:AMP | London | Ordinary Share | GB00B0DJNP99 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.15 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMAMP
RNS Number : 4898R
Amphion Innovations PLC
09 December 2016
Amphion Innovations plc
("Amphion" or "the Company")
Directors Dealings
London and New York, 9 December 2016 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that on 8 December 2016 it granted options over ordinary shares in the Company ("Options") to certain of its Directors as follows:
Director Amount Strike Vesting Price ---------------------- -------- ----------- ------------------- Richard Mansell-Jones 600,000 2.38 pence Monthly over a 36 month period ---------------------- -------- ----------- ------------------- Richard Mansell-Jones 563,000 2.38 pence Monthly over a 12 month period ---------------------- -------- ----------- ------------------- Paul Kennedy 375,000 2.38 pence Monthly over a 12 month period ---------------------- -------- ----------- ------------------- Miroslaw Izienicki 375,000 2.38 pence Monthly over a 12 month period ---------------------- -------- ----------- -------------------
All Options commence vesting backdated from 1 August 2016.
The strike price is based on the closing price on 8 December 2016, and the Options are exercisable on the date of vesting. Authority for the allotment of ordinary shares under the Share Option Scheme has already been given by the Shareholders in general meeting.
For further information please contact:
Amphion Innovations
Charlie Morgan
+1 212 210 6224
Yellow Jersey PR
Charles Goodwin / Dominic Barretto
+44 (0)7747 788 221
Panmure Gordon Limited (Nominated Adviser and Corporate Broker)
Freddy Crossley / Duncan Monteith (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500
Northland Capital Partners Limited (Joint Corporate Broker)
Patrick Claridge / David Hignell (Corporate Finance)
John Howes (Corporate Broking)
+44 (0)20 3861 6625
Plumtree Capital Limited (Financial Adviser)
Stephen Austin
+44 (0)20 7183 2493
+646 568 7502
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.
We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.
On the web: www.amphionplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEKLFBQLFZFBK
(END) Dow Jones Newswires
December 09, 2016 10:50 ET (15:50 GMT)
1 Year Amphion Innovations Chart |
1 Month Amphion Innovations Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions